AnaptysBio Inc., a clinical-stage biotechnology company, will host a virtual investor event on October 14 to provide an overview of ANB033, its CD122 antagonist. The presentation will cover ANB033's mechanism of action, preclinical and initial Phase 1a data in healthy volunteers, as well as celiac disease biology and the design of its Phase 1b trial.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AnaptysBio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536776-en) on September 29, 2025, and is solely responsible for the information contained therein.